RT Journal Article
SR Electronic
T1 Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.20.21257393
DO 10.1101/2021.05.20.21257393
A1 Blandine Monel
A1 Delphine Planas
A1 Ludivine Grzelak
A1 Nikaïa Smith
A1 Nicolas Robillard
A1 Isabelle Staropoli
A1 Pedro Goncalves
A1 Françoise Porrot
A1 Florence Guivel-Benhassine
A1 Nathalie Demory Guinet
A1 Julien Rodary
A1 Julien Puech
A1 Victor Euzen
A1 Laurent Bélec
A1 Galdric Orvoen
A1 Léa Nunes
A1 Véronique Moulin
A1 Jacques Fourgeaud
A1 Maxime Wack
A1 Sandrine Imbeaud
A1 Pascal Campagne
A1 Darragh Duffy
A1 James P. Di Santo
A1 Timothée Bruel
A1 Hélène Péré
A1 David Veyer
A1 Olivier Schwartz
YR 2021
UL http://medrxiv.org/content/early/2021/05/22/2021.05.20.21257393.abstract
AB The mechanisms that allowed for the SARS-CoV-2 B.1.1.7 variant to rapidly outcompete pre-existing variants in many countries remain poorly characterized. Here, we analyzed viral release, anti-SARS-CoV-2 antibodies and cytokine production in a retrospective series of 427 RT–qPCR+ nasopharyngeal swabs collected in COVID-19 patients harbouring either non-B.1.1.7 or B.1.17 variants. We utilized a novel rapid assay, based on S-Fuse-T reporter cells, to quantify infectious SARS-CoV-2. With both non-B.1.1.7 and B.1.1.7 variants, viral titers were highly variable, ranging from 0 to >106 infectious units, and correlated with viral RNA levels. Lateral flow antigenic rapid diagnostic tests (RDTs) were positive in 96% of the samples harbouring infectious virus. About 67 % of individuals carried detectable infectious virus within the first two days after onset of symptoms. This proportion decreased overtime, and viable virus was detected up to 14 days. Samples containing anti-SARS-CoV-2 IgG or IgA did not generally harbour infectious virus. The proportion of individuals displaying viable virus or being RDT-positive was not higher with B.1.1.7 than with non-B.1.1.7 variants. Ct values were slightly but not significantly lower with B.1.1.7. The variant was characterized by a fast decrease of infectivity overtime and a marked release of 17 cytokines (including IFN-β, IP-10, IL-10 and TRAIL). Our results highlight differences between non-B.1.1.7 and B.1.1.7 variants. B.1.1.7 is associated with modified viral decays and cytokine profiles at the nasopharyngeal mucosae during symptomatic infection.Competing Interest StatementL.G., I.S., T.B., J.B., F.G.-B., and O.S. are coinventors on provisional patent submitted by Institut Pasteur entitled: S-Flow: a FACS-based assay for serological analysis of SARS-CoV2 infection (no. US 63/020,06).Funding StatementWork in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX- 62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR, Fondation pour la Recherche Medicale. DP is supported by the Vaccine Research Institute. LG is supported by the French Ministry of Higher Education, Research and Innovation. DD and JDS are funded by the ANR-20-COVI-0053 grant. The funders of this study had no role in study design, data collection, analysis and interpretation, or writing of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our observational work was carried out in accordance with the Declaration of Helsinki with no sampling addition to usual procedures. Swab specimens were obtained for standard diagnostic following medical prescriptions in our hospital. The project was evaluated by the ethics committee (Comite d'ethique de la recherche AP-HP Centre) affiliated to the AP-HP (Assitance publique des Hopitaux de Paris). It obtained an approval (IRB registration # 00011928) on February 17, 2021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data supporting the findings of this study are available within the paper and are available from the corresponding author upon request. The viral sequences have been deposited to GISAID and accession numbers are available upon request.